CClinicalTrials.gg
Not yet recruitingNCT07515482Updated Jun 11, 2026

Manual Acupuncture for Acute Primary Tinnitus

An interventional study of Manual acupuncture and Sham acupuncture in Tinnitus, sponsored by Dan Bing. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Dan Bing · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This clinical trial aims to assess the efficacy of manual acupuncture for patients with acute primary tinnitus.

Read the detailed description

This is a multicentre, randomised, controlled clinical trial with blinded participants, outcome assessment and statistician. The total trial period will be 14 weeks, including two weeks of baseline assessment, four weeks of treatment, and eight weeks of follow-up. A total of 180 patients with acute primary tinnitus will be randomized in a 1:1:1 ratio to receive 10 sessions of manual acupuncture, 10 sessions of sham acupuncture, or usual care alone over 4 weeks. Informed consent will be obtained from each patient before randomization.

02

Conditions studied

  • Tinnitus

Browse trials for

Keywords

  • Tinnitus
  • acupuncture
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Aged 18-65 years, male or female;
  2. Primary complaint is persistent tinnitus (unilateral or bilateral);
  3. Meet the diagnostic criteria for primary tinnitus according to the 2014 Clinical Practice Guideline developed by the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF);
  4. Had continuous tinnitus ≥2 weeks and \<6 months;
  5. Tinnitus should be bothersome, with a screening THI score 28-76;
  6. Acupuncture naive;
  7. Able to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Objective tinnitus;
  2. Pulsatile tinnitus;
  3. Diagnosed as secondary tinnitus as evaluated by audiologists and clinicians(Menière's disease, temporomandibular joint disorder or other diseases);
  4. Had evidence of conductive hearing loss (confirmed by abnormal otoscopy or tympanogram);
  5. Had contraindications for acupuncture, including curent pregnant, severe anemia, coagulation disorders, etc;
  6. Having difficulties in expressing their symptoms clearly( severe mental disorders or cognitive impairment);
  7. Currently suffering from other serious acute or chronic organic diseases, such as cerebrovascular, cardiovascular, liver, kidney, hematological diseases, infectious diseases, or malignant tumors;
  8. Has received intratympanic injection, postauricular injection, corticosteroids, or other medications for tinnitus treatment (includingTraditional Chinese Medicine or proprietary Chinese medicines) within the past 2 weeks or at baseline;
  9. Participated in other clinical trials, particularly those closely related to tinnitus treatment, such as sound therapy;
  10. have a strong desire for medication treatment.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Manual acupuncture group

    Ten sessions of 30 minute manual acupuncture are deivered during a four-week treatment period.

    Other: Manual acupuncture · Behavioral: Usaual care

  • Sham comparator
    Sham acupuncture

    Ten sessions of 30 minute sham acupuncture are deivered during 4 weeks.

    Other: Sham acupuncture · Behavioral: Usaual care

  • Other
    Usual care

    Health education and guidance related to tinnitus

    Behavioral: Usaual care

Interventions

  • OtherManual acupuncture

    Ten manual acupuncture sessions will be delivered over 4 weeks, with treatment frequency decreasing from 3 sessions per week for the first 2 weeks to 2 sessions per week for the remaining weeks.

  • OtherSham acupuncture

    Ten manual acupuncture sessions will be delivered over 4 weeks, with treatment frequency decreasing from 3 sessions per week for the first 2 weeks to 2 sessions per week for the last 2 weeks.

  • BehavioralUsaual care

    Health education and standard evaluation related to tinnitus

05

What researchers measure

Primary outcomes

  1. Tinnitus Handicap Inventory (THI, 0-100)

    25-item measure of tinnitus-related handicap; total score 0-100, higher scores indicate greater handicap. In details, 0-16 points indicate no handicap; 18-36 points indicate mild handicap;38-56 points indicate moderate handicap; 58-76 points indicate severe handicap and \>76 points indicate catastrophic handicap.

    Time frame: Baseline visit, end of treatment at 4 weeks after randomization, post-treatment at 8 weeks after randomization and 12 weeks after randomization.

  2. Tinnitus Functional Index (TFI, 0-100)

    25-item self-report measure of tinnitus-related functional impact; total score 0-100, higher scores indicate greater impairment.

    Time frame: Baseline visit, end of treatment at 4 weeks after randomization, post-treatment at 8 weeks after randomization and 12 weeks after randomization.

Secondary outcomes

  1. Effective response rate of THI

    Effective response rate of THI is defined as the proportion of patients with a THI score decrease of ≥7 points.

    Time frame: End of treatment at 4 weeks after randomization, 8 weeks after randomization and 12 weeks after randomization.

  2. Effective response rate of TFI.

    Effective response rate of TFI is defined as the proportion of patients with a TFI score decrease of ≥13 points.

    Time frame: End of treatment at 4 weeks after randomization, 8 weeks after randomization and 12 weeks after randomization.

  3. Visual Analogue Scale (VAS) for aural fullness

    We will use a 10-mm Visual Analogue Scale (VAS) (0 = no tinnitus, 10 = the most loud of tinnitus) to assess aural fullness.

    Time frame: Baseline visit, end of treatment at 4 weeks after randomization, post-treatment at 8 weeks after randomization and 12 weeks after randomization.

  4. Visual Analogue Scale (VAS) for tinnitus

    The VAS will be used to assess the intensity of tinnitus. 0 indicates "no aural fullness", and 10 indicates "the most severe aural fullness".

    Time frame: Baseline visit, end of treatment at 4 weeks after randomization, post-treatment at 8 weeks after randomization and 12 weeks after randomization.

  5. The Pittsburgh Sleep Quality Index (PSQI)

    The pittsburgh Sleep Qual-ityIndex (PSQI) is a self-rated questionnaire which assesses sleep quality and disturbances over a 1-month time interval. It has 19 questions which can be grouped into seven categories: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep dis-turbances, use of sleeping medication, and daytime dysfunction.The PSQI total score ranges from 0 to 21, with higher scores indicating worse sleep quality.

    Time frame: Baseline visit, end of treatment at 4 weeks after randomization, post-treatment at 8 weeks after randomization and 12 weeks after randomization.

  6. The Zung Self-Rating Depression Scale(SDS)

    The Zung Self-Rating Depression Scale(SDS) will be adopted to assess depression.

    Time frame: Baseline visit, end of treatment at 4 weeks after randomization, post-treatment at 8 weeks after randomization and 12 weeks after randomization.

  7. The Zung Self-Rating Anxiety Scale(SAS)

    The Zung Self-Rating Anxiety Scale(SAS) will be adopted to assess anxiety.

    Time frame: Baseline visit, end of treatment at 4 weeks after randomization, post-treatment at 8 weeks after randomization and 12 weeks after randomization.

  8. World Health Organization Quality of Life-BREF questionnaire(WHOQOL-BREF)

    Quality of life assessed using the World Health Organization Quality of Life-BREF (WHOQOL-BREF), yielding domain scores and an overall score (0-100; higher scores indicate better quality of life).

    Time frame: Baseline visit, end of treatment at 4 weeks after randomization, post-treatment at 8 weeks after randomization and 12 weeks after randomization.

  9. Patient-Doctor Relationship Questionnaire (PDRQ-9)

    Patient-Doctor Relationship Questionnaire (PDRQ-9) is to assess patient-doctor relationship.

    Time frame: Baseline visit, end of treatment at 4 weeks after randomization, post-treatment at 8 weeks after randomization and 12 weeks after randomization.

  10. Adverse Events

    Adverse events assessed each acupuncture treatment visit using a acupuncture adverse events questionnaire recording presence and severity of side effects (e.g., subcutaneous hemorrhage, minor bleeding) related to acupuncture, plus event frequency.

    Time frame: Up to 4 weeks (manual acupuncture/sham acupuncture sessions 1-10)

  11. Assessment of blinding

    At the end of the study, we will determine the maintenance of blinding of patients by asking them whether they thought the needles had penetrated the skin.

    Time frame: At 12 weeks after randomization

  12. Acupuncture expectancy scale(AES)

    The Acupuncture Expectancy Scale (AES) will be completed by participants in the verum and sham acupuncture groups at baseline and at the end of treatment (4 weeks after randomization). The questionnaire will not be administered to the usual care group.

    Time frame: Baseline visit, and end of treatment at 4 weeks after randomization,.

  13. Massachusetts General Hospital Acupuncture Sensation Scale(MASS)

    The Massachusetts General Hospital Acupuncture Sensation Scale, which includes twelve specific descriptors-soreness, aching, deep pressure, heaviness, fullness or distension, tingling, numbness, sharp pain, dull pain, warmth, cold, and throbbing-as well as an open field for patients to describe the sensation in their own words, will be administered following a brief explanation of de qi sensations by the acupuncturist to participants in the verum acupuncture and sham acupuncture groups, while the usual care group will not receive this questionnaire.

    Time frame: Up to 4 weeks (manual acupuncture/sham acupuncture sessions 1-10)

  14. Auditory Sensitivity Scale

    Auditory Sensitivity Scale is a self-report questionnaire consisting of general questions on tinnitus and sound intolerance, along with 25 items rated on different scoring scales (e.g., 0/2/5, 0/1/2, 0/10), and provides a severity classification based on the total score: 31-55 for mild, 56-80 for moderate, 81-100 for severe, and 101-126 for very severe.

    Time frame: Baseline visit, end of treatment at 4 weeks after randomization, post-treatment at 8 weeks after randomization and 12 weeks after randomization.

Other outcomes

  1. 10-item short version of the Big Five Inventory (BFI-10)

    Personality is assessed by a10-item short version of the Big Five Inventory (BFI-10).

    Time frame: Baseline visit(before randomization)

  2. Pure-Tone Audiometry(PTA)

    Pure tone audiometry is conducted under standard soundproof conditions using the Hughson-Westlake method to obtain the air conduction threshold (bone conduction threshold is only used for diagnosis, to determine whether there is conductive hearing loss, and to assist in the screening process; statistical analysis only uses the air conduction threshold). The standard test frequencies range from 0.25 to 8 kHz. If conditions permit, extended high frequencies (Extended High Frequency, EHF; ≥ 9-16 kHz) are added, and necessary masking is performed in accordance with the norms.

    Time frame: Baseline visit(before randomization)

06

Study locations

1 site
  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,
    Wuhan, Hubei 430030, China
07

References and documents

Individual participant data

Plan to share: Yes — IPD after de-identification can be shared on individual request to the principal investigator at didibing1981@aliyun.com

Supporting information: Study protocol, Sap, Icf

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07515482
Lead sponsor
Dan Bing
Collaborators
Hubei Xinhua Hospital, Wuhan No.1 Hospital, The Third People's Hospital of Hubei Province, Taihe Hospital, Qianjiang Central Hospital
Responsible party
Dan Bing (Associate Professor, Tongji Hospital) — Sponsor-investigator
First posted
Apr 7, 2026
Start date
Jun 15, 2026 (estimated)
Primary completion
Oct 30, 2027 (estimated)
Completion
Dec 12, 2027 (estimated)
Last update
Jun 11, 2026

Study contacts

Dan Bing, PhD
Contact
didibing1981@aliyun.com
86+13971058388
Dan Bing, PhD
Contact
didibing1981@aliyun.com
86-13971058388
Dan Bing, PhD
principal investigator · Tongji Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion